Exploring and validating surrogate endpoints in colorectal cancer

[1]  D. Sargent.  Time-dependent patterns of failure and treatment benefit from adjuvant therapy for resectable colon cancer: Lessons from the 20,800-patient (pt) ACCENT dataset , 2007 .

[2]  Daniel J Sargent,et al.  Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Buyse,et al.  Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[5]  G. Molenberghs,et al.  The validation of surrogate endpoints in meta-analyses of randomized experiments. , 2000, Biostatistics.

[6]  R. Plackett.  A Class of Bivariate Distributions , 1965 .

[7]  G. Nahler.  disease free survival (DFS) , 2009 .

[8]  M. Buyse,et al.  Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation. , 2006, Pharmaceutical statistics.

[9]  José Cortiñas Abrahantes,et al.  Validation in the Case of Two Failure-time Endpoints , 2005 .

[10]  G. Molenberghs,et al.  Validation of surrogate end points in multiple randomized clinical trials with failure time end points , 2001 .